Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis

被引：0
作者：
Hart, A. [1 ,2 ]
Martin-Arranz, M. D. [3 ]
Laharie, D. [4 ]
Matsuoka, K. [5 ]
Dhesi, E. [6 ]
Redondo, I. [6 ]
Baygani, S. [6 ]
Zaremba-Pechmann, L. [7 ]
Samaan, K. [6 ]
Navabi, S. [8 ]
机构：
[1] St Marks Hosp, London, England
[2] Imperial Coll, Dept Metab Digest & Reprod, London, England
[3] Hosp La Paz Inst Hlth Res, Dept Gastroenterol, Madrid, Spain
[4] Univ Bordeaux, Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France
[5] Toho Univ, Div Gastroenterol & Hepatol, Sakura Med Ctr, Dept Internal Med, Sakura, Japan
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] HaaPACS GmBH, Stat, Schriesheim, Germany
[8] United Med Doctors, Gastroenterol Hepatol & Obes Med, Long Beach, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP14
引用
收藏
页码：I27 / I28
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [42] Biological Therapy for Ulcerative Colitis: What is after Anti-TNF
    Fiorino, Gionata
    Cesarini, Monica
    Danese, Silvio
    CURRENT DRUG TARGETS, 2011, 12 (10) : 1433 - 1439
  • [43] Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies
    Friedrich, Stuart
    Chua, Laiyi
    Adams, David H.
    Crandall, Wallace
    Zhang, Xin Cindy
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 435 - 447
  • [44] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
    Andrews, J. M.
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
  • [45] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
  • [46] COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US
    Wang, Xuan
    Bakker, Lytske
    Upadhyay, Navneet
    Hartz, Susanne
    Treur, Maarten
    Svedbom, Axel
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S44 - S45
  • [47] A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE, ANTI-TNF ALPHA AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
    Rubin, David T.
    Lee, Scott D.
    Flores, Lucky
    Albizu-Angulo, Gustavo
    Scherl, Ellen J.
    Saini, Surinder
    Patel, Shipra
    Cheng, Yi-Lin I.
    Cheng, Ting-Ying
    Lin, Shih-Yao
    GASTROENTEROLOGY, 2020, 158 (06) : S951 - S952
  • [48] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S214 - S214
  • [49] Efficacy of Infliximab after failure of subcutaneous anti-TNF agents in patients with moderate-to-severe ulcerative colitis
    Viazis, N.
    Tsoukali, E.
    Galanopoulos, M.
    Pontas, C.
    Karampekos, G.
    Filippidis, G.
    Giouleme, O.
    Theocharis, G.
    Tzouvala, M.
    Archavlis, E.
    Christidou, A.
    Mantzaris, G. J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S366 - S367
  • [50] Does failure to respond to one anti-TNF agent in Ulcerative Colitis predict treatment failure with other anti-TNF agents?
    AlAlawi, F.
    Keegan, D.
    Byrne, K.
    Mulcahy, H.
    Cullen, G.
    Doherty, G.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S254 - S254
12345